EGTTF yields 1052.63% · PFE yields 6.13%● Live data
📍 EGTTF pulled ahead of the other in Year 1
Combined, EGTTF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of EGTTF + PFE for your $10,000?
EYEFI Group Technologies Inc., an electronics and software engineering company, develops spatial, predictive, approximation, and radial convolution (SPARC) technology. Its products include EYEfi Cloud, a platform that offers remote monitoring, intelligence gathering, and situational awareness solutions; EYEfi Sensors, which is used for monitoring and intelligence gathering applications from industrial-grade camera sensors; EYEfi SPARC, a situational awareness technology for government and industry; and EYEfi SPARC (mobile), a solution that spatially enables smartphones, wearable technology, and UAVs. The company's SPARC solution turns sensors, cameras, or smartphone devices (fixed, mobile, airborne, portable, or handheld) into target co-ordinate acquisition systems. Its solutions also include Industrial Internet of Things (IIoT) hardware sensor product and cloud application (Smart Waste) for waste bins and smart drain for storm water pits. The company, through resellers, serves government and industry customers in the infrastructure and asset management, emergency management, and incident response markets primarily in Australia and New Zealand. EYEFI Group Technologies Inc. was incorporated in 2018 and is headquartered in Collingwood, Australia.
Full EGTTF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.